DE3342870A1 - Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen - Google Patents

Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen

Info

Publication number
DE3342870A1
DE3342870A1 DE19833342870 DE3342870A DE3342870A1 DE 3342870 A1 DE3342870 A1 DE 3342870A1 DE 19833342870 DE19833342870 DE 19833342870 DE 3342870 A DE3342870 A DE 3342870A DE 3342870 A1 DE3342870 A1 DE 3342870A1
Authority
DE
Germany
Prior art keywords
antibodies
digitalis
fab
column
papain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19833342870
Other languages
German (de)
English (en)
Inventor
Hans-Georg Dr.Rer.Nat. Batz
Herbert Dr.med. Jungfer
Helmut Dr.rer.nat. 8132 Tutzing Lenz
Albert Dr.rer.nat. 8124 Seeshaupt Röder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Priority to DE19833342870 priority Critical patent/DE3342870A1/de
Priority to US06/563,217 priority patent/US4742159A/en
Priority to CA000466633A priority patent/CA1242393A/en
Priority to AT84113943T priority patent/ATE64141T1/de
Priority to EP84113943A priority patent/EP0143413B1/de
Priority to DE8484113943T priority patent/DE3484673D1/de
Priority to SU843817568A priority patent/SU1455999A3/ru
Priority to ES537909A priority patent/ES8600770A1/es
Priority to JP59248259A priority patent/JPS60132922A/ja
Publication of DE3342870A1 publication Critical patent/DE3342870A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE19833342870 1983-11-26 1983-11-26 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen Withdrawn DE3342870A1 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE19833342870 DE3342870A1 (de) 1983-11-26 1983-11-26 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen
US06/563,217 US4742159A (en) 1983-11-26 1983-12-19 Digitalis antibodies, process for the preparation thereof and the use thereof for the therapy of digitalis intoxications
CA000466633A CA1242393A (en) 1983-11-26 1984-10-30 Digitalis antibodies, process for the preparation thereof and the use thereof for the therapy of digitalis intoxications
AT84113943T ATE64141T1 (de) 1983-11-26 1984-11-17 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen.
EP84113943A EP0143413B1 (de) 1983-11-26 1984-11-17 Digitalis-Antikörper, Verfahren zu ihrer Herstellung und ihre Verwendung zur Therapie von Digitalis-Intoxikationen
DE8484113943T DE3484673D1 (de) 1983-11-26 1984-11-17 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen.
SU843817568A SU1455999A3 (ru) 1983-11-26 1984-11-23 Способ получени дигиталис-антител
ES537909A ES8600770A1 (es) 1983-11-26 1984-11-23 Procedimiento para la preparacion de anticuerpos contra digitalis
JP59248259A JPS60132922A (ja) 1983-11-26 1984-11-26 ジギタリス抗体の製造法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833342870 DE3342870A1 (de) 1983-11-26 1983-11-26 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen

Publications (1)

Publication Number Publication Date
DE3342870A1 true DE3342870A1 (de) 1985-06-05

Family

ID=6215371

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19833342870 Withdrawn DE3342870A1 (de) 1983-11-26 1983-11-26 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen
DE8484113943T Expired - Lifetime DE3484673D1 (de) 1983-11-26 1984-11-17 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE8484113943T Expired - Lifetime DE3484673D1 (de) 1983-11-26 1984-11-17 Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen.

Country Status (8)

Country Link
US (1) US4742159A (OSRAM)
EP (1) EP0143413B1 (OSRAM)
JP (1) JPS60132922A (OSRAM)
AT (1) ATE64141T1 (OSRAM)
CA (1) CA1242393A (OSRAM)
DE (2) DE3342870A1 (OSRAM)
ES (1) ES8600770A1 (OSRAM)
SU (1) SU1455999A3 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849352A (en) 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
US4841024A (en) * 1986-09-15 1989-06-20 Becton Dickinson And Company Purification of antibodies
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
JPH0623761B2 (ja) * 1988-12-09 1994-03-30 株式会社ピーシーシーテクノロジー 配糖化した化合物を生産する細胞の検出方法
US5328834A (en) * 1989-09-08 1994-07-12 Unisyn Technologies, Inc. Method for preparing immunoglobulin fragments
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
JP4837221B2 (ja) * 2000-05-25 2011-12-14 株式会社カネカ 強心配糖体の吸着材、吸着除去方法および吸着器
FR2810667B1 (fr) * 2000-06-23 2004-09-03 Warner Lambert Co Procede d'isolement et de purification d'une proteine, et proteine obtenue
US6802966B2 (en) * 2001-08-14 2004-10-12 W. R. Grace & Co. Conn. Solid compositions for selective adsorption from complex mixtures
US6987079B2 (en) * 2001-08-14 2006-01-17 W.R. Grace & Co.-Conn. Supported catalyst systems
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
AU2007269714A1 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
EP2370092A1 (en) 2008-12-03 2011-10-05 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
AU2012294814A1 (en) 2011-08-05 2014-02-27 Research Development Foundation Improved methods and compositions for modulation of Olfml3 mediated angiogenesis
WO2014066590A1 (en) 2012-10-24 2014-05-01 Research Development Foundation Jam-c antibodies and methods for treatment of cancer
CN106659909B (zh) 2013-08-21 2022-01-11 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CA3015839A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System Connexin (cx)43 hemichannel-binding antibodies and uses thereof
ES2883297T3 (es) 2016-03-29 2021-12-07 Stcube Inc Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
JP2019528251A (ja) 2016-07-20 2019-10-10 エスティーキューブ，インコーポレイテッド グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法
AU2018277838C1 (en) 2017-05-31 2025-08-07 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
US11542331B2 (en) 2017-06-06 2023-01-03 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
US11464784B2 (en) 2017-09-15 2022-10-11 The Regents Of The University Of California Inhibition of aminocylase 3 (AA3) in the treatment of cancer
US20200290978A1 (en) 2017-09-26 2020-09-17 The Regents Of The University Of California Compositions and methods for treating cancer
EP3802616A4 (en) 2018-06-04 2022-03-30 University of Maryland, Baltimore PROCEDURES FOR THE PREVENTION OF AN ACUTE KIDNEY LESION
WO2021062323A1 (en) 2019-09-26 2021-04-01 Stcube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
US20220356248A1 (en) 2019-10-09 2022-11-10 Stcube & Co Antibodies specific to glycosylated lag3 and methods of use thereof
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
CN113736744B (zh) * 2021-10-14 2023-07-18 江南大学 洋地黄毒苷单克隆抗体杂交瘤细胞株及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3790475A (en) * 1972-03-27 1974-02-05 Corning Glass Works Porous glass support material
US4039652A (en) * 1973-10-11 1977-08-02 Miles Laboratories, Inc. Column method of immunoassay employing an immobilized binding partner
US4081246A (en) * 1976-05-03 1978-03-28 Beckman Instruments, Inc. Solid phase column immunoassay procedure employing novel immunochemical composites
US4081245A (en) * 1976-05-03 1978-03-28 Beckman Instruments, Inc. Immunoassay procedure employing novel immunochemical composites
US4232004A (en) * 1977-09-21 1980-11-04 American National Red Cross Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith
US4434234A (en) * 1981-04-02 1984-02-28 The Upjohn Company Method and kit for silver staining substances supported in matrix

Also Published As

Publication number Publication date
JPH0324480B2 (OSRAM) 1991-04-03
SU1455999A3 (ru) 1989-01-30
ES537909A0 (es) 1985-11-01
EP0143413A2 (de) 1985-06-05
ATE64141T1 (de) 1991-06-15
US4742159A (en) 1988-05-03
EP0143413B1 (de) 1991-06-05
DE3484673D1 (de) 1991-07-11
EP0143413A3 (en) 1988-07-20
ES8600770A1 (es) 1985-11-01
JPS60132922A (ja) 1985-07-16
CA1242393A (en) 1988-09-27

Similar Documents

Publication Publication Date Title
EP0143413B1 (de) Digitalis-Antikörper, Verfahren zu ihrer Herstellung und ihre Verwendung zur Therapie von Digitalis-Intoxikationen
EP0004940B1 (de) Verfahren zur radioimmunologischen Bestimmung von Prokollagen (Typ III) und Prokollagen-Peptid (Typ III), zur Herstellung von für das Verfahren geeignetem Prokollagen-Peptid (Typ III) und zur Herstellung von Anti-Prokollagen-Peptid (Typ III)-Serum
EP0447585B1 (de) Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates
DE3486453T2 (de) Monoklonale Antikörper gegen neue Faktor-VIII Gerinnungspolypeptide
CH634334A5 (de) Neues glycoprotein und verfahren zu dessen herstellung.
EP0014756B1 (de) Plazentaspezifisches Gewebsprotein PP10 und Verfahren zu seiner Anreicherung
DE2508132B2 (de) Verfahren zur Herstellung von HumaninununglobuUn-Derivaten und parenteral applizierbare Lösung hiervon
EP0037963B1 (de) Neues Protein PP9, Verfahren zu seiner Gewinnung sowie seine Verwendung
EP0100522A2 (de) Neues Protein (PP17), Verfahren zu seiner Anreicherung und Gewinnung sowie seine Verwendung
EP0165476A2 (de) Gewebeprotein PP18, Verfahren zu seiner Gewinnung sowie seine Verwendung
EP0029191B1 (de) Neues Protein PP11, ein Verfahren zu seiner Gewinnung und seine Verwendung
CH632091A5 (en) Process for the preparation of an antiserum directed against placenta-specific glycoprotein
DE3410694C2 (OSRAM)
DE2718325C2 (de) Leucinreiches 3,1-S-α↓2↓-Glykoprotein sowie dessen Verwendung
DE2353973C3 (de) Steroid-bindendes Globulin und Verfahren zu dessen Herstellung
DE3779914T2 (de) Neue lectine, abgeleitet von bakteriellen haaren.
DE3708198A1 (de) Verfahren zur isolierung von basalmembranproteinen aus menschlichen und tierischen geweben
DE2404265C3 (de) Verfahren zum Abreichen von Immunglobulinen
EP0151463B1 (de) Gewebeprotein PP19, Verfahren zu seiner Gewinnung sowie seine Verwendung
EP0137345B1 (de) Membranassoziierte Proteine (MP2), Verfahren zu ihrer Gewinnung sowie ihre Verwendung
DE2533183C3 (de) Verfahren zum Herstellen gereinigter Immunglobuline
DE2634584C3 (de) Atoxisches, immunogenes Produkt aus Tetanus-Toxin
DE10065227A1 (de) Verfahren zur Isolierung und Reinigung von Eigelb-Antikörpern aus Vogeleiweiß und Verwendung von dadurch erhaltenen Eigelb-Antikörpern
DE1959608C (de) Verfahren zur Gewinnung von AntiSerum für die Hepatomdiagnose
EP0155676A2 (de) Verfahren zur Gewinnung der globulären Domäne von Basalmembrankollagen und immunologische Bestimmung von Basalmembranmaterial und Autoantikörpern

Legal Events

Date Code Title Description
8141 Disposal/no request for examination